Starling Oncology, Inc.
NASDAQSTLN heads into its August 11 earnings report on the back of a sharp, sudden re-rating — and the data tells a story of bullish conviction without much short-side resistance. The stock gained 28% in a single session on August 7, extending a 31% weekly move to close at $6.39. That follows a positive print earlier this month: the previous earnings event on August 6 also produced a…
Snapshot as of 8 Aug 2026
STLN heads into its August 11 earnings report on the back of a sharp, sudden re-rating — and the data tells a story of bullish conviction without much short-side resistance. The stock gained 28% in a single session on…
The Oncology Institute enters the back half of June with a rare combination: a stock up 28% over the past month, analysts actively raising targets, and a lending market so loose it barely registers as a short thesis at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for STLN — free to start on ORTEX.
Sign up for free →Open STLN on ORTEX